Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

被引:0
作者
Maria Boesing
Kristin Abig
Michael Brändle
Martin Brutsche
Emanuel Burri
Björn C. Frye
Stéphanie Giezendanner
Jan C. Grutters
Philippe Haas
Justian Heisler
Fabienne Jaun
Anne B. Leuppi-Taegtmeyer
Giorgia Lüthi-Corridori
Joachim Müller-Quernheim
Reto Nüesch
Wolfgang Pohl
Frank Rassouli
Jörg D. Leuppi
机构
[1] University Clinic of Medicine,Faculty of Medicine
[2] Cantonal Hospital Baselland,Department of Pneumology
[3] University of Basel,Division of Heart & Lungs
[4] Cantonal Hospital St. Gallen,Department of Clinical Pharmacology and Toxicology
[5] Medical Center University of Freiburg,undefined
[6] St. Antonius Hospital Nieuwegein,undefined
[7] University Medical Center Utrecht,undefined
[8] AdVita Lifescience GmbH,undefined
[9] University Hospital Basel,undefined
[10] University of Basel,undefined
[11] Hospital Schwyz,undefined
[12] Karl Landsteiner Institute for Clinical and Experimental Pneumology,undefined
[13] Clinic Hietzing,undefined
来源
Trials | / 23卷
关键词
Aviptadil; VIP; COVID-19; ARDS; SARS-CoV-2;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 231 条
[1]  
Chen N(2020)Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet (London, England) 395 507-513
[2]  
Zhou M(2021)Dexamethasone in hospitalized patients with COVID-19 N Engl J Med 384 693-704
[3]  
Dong X(2021)Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial Lancet Respir Med 9 1407-1418
[4]  
Qu J(2021)Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab N Engl J Med 385 1941-1950
[5]  
Gong F(2022)Early remdesivir to prevent progression to severe COVID-19 in outpatients N Engl J Med 386 305-315
[6]  
Han Y(2022)Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19 N Engl J Med 386 1397-1408
[7]  
Horby P(2022)Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients N Engl J Med 386 509-520
[8]  
Lim WS(2022)Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial Lancet Glob Health 10 e42-e51
[9]  
Emberson JR(2021)REGEN-COV antibody combination and outcomes in outpatients with COVID-19 N Engl J Med 385 e81-179
[10]  
Mafham M(2021)Emerging treatment strategies for COVID-19 infection Clin Exp Med 21 167-771